International Stem Cell (ISCO) Payables (2010 - 2026)

International Stem Cell (ISCO) has reported Payables for 17 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 2.75% year-over-year to $3.6 million in Q2 2026; TTM through Jun 2026 was $3.6 million, a 2.75% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, down 2.04% from the prior year.
• Payables was $3.6 million for Q2 2026 at International Stem Cell, up from $3.5 million in the prior quarter.
• Over five years, Payables peaked at $3.9 million in Q2 2024 and troughed at $3.5 million in Q4 2025.
• A 5-year average of $3.7 million and a median of $3.7 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables increased 14.74% in 2022 and declined 6.28% in 2024, its largest moves.
• Over 5 years, Payables stood at $3.6 million in 2022, then gained by 4.77% to $3.8 million in 2023, then retreated by 6.28% to $3.6 million in 2024, then decreased by 2.04% to $3.5 million in 2025, then rose by 1.65% to $3.6 million in 2026.
• The last three Payables figures came in at $3.6 million (Q2 2026), $3.5 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.